Skip links

Sublocade® (buprenorphine extended-release)

Full Name Sublocade® (buprenorphine extended-release)
Drug Sublocade
Manufacturer Indivior
Route of Administration Subcutaneous
Site of Care Healthcare Facility
Approved Indication The treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days
Disease Opioid Dependence
Therapeutic Area Mental Health & Addiction
Enrollment Form Link Sublocade Enrollment Form
Phone Number 800-241-1534
Fax Number 877-785-7737
Product Website